Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by status in patients with advanced ovarian carcinomas.

Objective: Treatment of high-grade serous ovarian carcinomas relies on surgery and chemotherapy, potentially followed by bevacizumab and/or poly (ADP-ribose) polymerase inhibitors (PARPi). The modeled CA-125 ELIMination rate constant K (KELIM) is a pragmatic indicator of tumor primary chemosensitivity. Although it is well established that mutations are associated with platinum sensitivity, the relationship between status and KELIM score has yet to be elucidated.

Validation of RUBY for Breast Cancer Knowledge Extraction From a Large French Electronic Medical Record System.

Purpose: RUBY is a tool for extracting clinical data on breast cancer from French medical records on the basis of named entity recognition models combined with keyword extraction and postprocessing rules. Although initial results showed a high precision of the system in extracting clinical information from surgery, pathology, and biopsy reports (≥92.7%) and good precision in extracting data from consultation reports (81.

SENODAY: A New Perspective of Handling Breast Cancer.

Background: To evaluate the feasibility of a same day breast cancer diagnosis and management protocol, consequently decreasing time to treatment and immediately reassuring patients with benign diagnosis.

Materials And Methods: A total of 60 women underwent breast exam during SENODAY in our cancer center between January 2020 and December 2022. Patients are first seen by a breast surgeon who mentions whether the patient's history and physical exam are suspicious of malignancy.

Breast Cancer and SARS-Cov2: Lessons from a Pandemic.

Background/aim: The COVID-19 pandemic introduced drastic containment measures, which had a direct impact on breast cancer management. During the first wave, a delay in care and a decrease in new consultation numbers was observed. It would be interesting to study the resulting long-term consequences on breast cancer presentation and time to first treatment.

Efficacy of chemotherapy according to status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.

Objective: Chemotherapy for high-grade serous ovarian cancers in platinum-sensitive relapse includes carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. According to data, mutated patients are sensitive to replicative stress agents but status is not yet used for the choice of chemotherapy at relapse. Our aim was to assess these doublets according to status in first platinum-sensitive relapse.